University of California

The University of Texas System

Quest Pharmatech, Inc.

Oncoquest Inc.

Manuel L Penichet

Gustavo Helguera

Sherie L Morrison

Birgit Corinna Schultes

Christopher F Nicodemus

Renato J Aguilera

Jose A Rodriguez

Tracy R Wells

Tracy R Daniels

Rosendo Luria-Perez

Jay Dela Cruz

Lisan Peng

Subhas S Karki

Sujeet Kumar

The inventors have used a differential nuclear staining (DNS) assay to discover compounds with cytotoxic activity against the CEM cell line that has been determined to be highly sensitive to a variety of anti-cancer compounds. Compounds were synthesized based on a pyrazole backbone structure. Several newly synthesized compounds have been tested to identify the compounds with highest activity. One compound identified is the SSK-3 compound which has been tested on cancer cell lines and determined that it induced apoptosis via phosphatidylserine membrane exposure and activation of caspase 3 in the CEM lymphoma cell line.

Pyrazole derivatives with anticancer activity

Disclosed herein are methods and compositions for treating cancer. In particular, the in vivo efficacy of unconjugated anti-TfR antibodies, such as ch128.1, are disclosed herein.

Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer

The present invention provides monoclonal IgE antibodies comprising Fc epsilon (&#x3b5;) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).

IgE antibodies for the treatment of cancer

Disclosed herein are polypeptides which comprise all or part of an antibody linked to all or part of a cytokine. The cytokine sequences of the polypeptides have a modified heparin binding region which disrupts, inhibits, or reduces the ability of the cytokine to bind a heparin compound as compared to a corresponding cytokine having an unmodified heparin binding region. Also disclosed are methods of treating cancer, inducing cell proliferation, and reducing the non-specific binding and/or non-specific localization of the polypeptides.

Antibody fusion with IL-12 proteins with disrupted heparin-binding activity

The present invention provides methods of use of various antibody-immunostimulant fusion proteins as adjuvants of antigenic protein vaccinations to elicit humoral and/or cellular immune responses in vaccinated subjects. Compositions which include these fusion proteins and innate and/or exogenous antigenic proteins are also provided.

Antibody fusion proteins: effective adjuvants of protein vaccination

Growing community of inventors

Los Angeles, CA, United States of America

Manuel L Penichet